Humana's Short Interest Jumps at a 3.7-Sigma Pace Before Thursday's Print

Humana reports third-quarter results on Thursday, and the most striking development in the run-up is not the stock's modest 5.7% monthly recovery to $410.41, but the sudden acceleration in bearish positioning over the past two weeks.

Short interest has climbed 31.5% over the past seven days, reaching 3.06% of the free float. That weekly move sits 3.7 standard deviations above Humana's typical weekly swing over the past year, making it one of the sharpest short-building episodes the stock has seen. The jump appears concentrated in the period after October 23, when shares outstanding on loan moved from roughly 2.75 million to above 3.6 million in under a week. Despite the pace of the move, the borrow market shows no sign of stress: availability runs at an extremely loose 7,517%, meaning there are roughly 75 shares available to lend for every one already borrowed, and the cost to borrow remains negligible at 0.26%. The infrastructure for further short-building is fully in place.

Options markets tell a consistent story. The put/call ratio has climbed to 1.19, its highest reading of the past year, and sits 1.5 standard deviations above its 20-day average of 1.05. That is the most defensively skewed options positioning Humana has seen in at least twelve months, and the drift has been sustained: the ratio has edged higher nearly every session since mid-October. The stock itself edged down 1.6% over the past week, broadly in line with managed care peers including UNH, CNC and ELV, which were off between 2.5% and 4.5%.

The debate around Humana centres on whether the company's Medicare Advantage business has genuinely turned a corner. Bulls point to the 500-basis-point improvement in Group MA margins and a 16% revenue gain at the CenterWell pharmacy and home-care unit as evidence that management's contract renegotiation effort is working. Bears argue the structural problem has not gone away: the company faces an estimated $3.5 billion headwind from deteriorating MA Star ratings, translating into roughly $22 of EPS drag for 2026, at a stock already trading at roughly 26 times earnings. Analyst sentiment shifted materially in early October, with a cluster of upgrades and target increases from firms including Barclays, Baird and Raymond James, pushing the consensus mean target to $465, about 13% above the current price. EPS momentum factor scores rank in the 90th percentile on both a 30-day and 90-day basis, suggesting estimate revisions have been running in the right direction.

The last comparable earnings print, in late July, produced a 5.7% one-day drop and an additional 6.4% decline over the following five sessions, suggesting that even when numbers improve, the market has punished guidance cautiously. Thursday's release will test whether the MA margin story is durable enough to absorb whatever the Star-ratings headwind means for forward numbers, and whether the recent short-building reflects informed hedging or a position that unwinds quickly on a clean print.